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Association Between Race/Ethnicity and Survival of
Melanoma Patients in the United States Over 3 Decades
A Secondary Analysis of SEER Data
Melissa Ward-Peterson, MPH, Juan M. Acun˜a, MD, MSc,
Mohammed K. Alkhalifah, MBBS student, Abdulrahman M. Nasiri, MBBS student,
Elharith S. Al-Akeel, MBBS student, Talal M. Alkhaldi, MBBS student,
Sakhr A. Dawari, MBBS student, and Sami A. Aldaham, MD
Abstract: Melanoma is a treatable and preventable skin cancer. It is
responsible for 75% of deaths among all skin cancers. Previous studies
have found that race/ethnicity may play a role in survival among
melanoma patients. However, there are no studies that cover 30 years
and take race into account for the U.S. population.
This study is a secondary analysis of the National Cancer Institute’s
Surveillance, Epidemiology, and End Result (SEER) Program. Adults
with primary cutaneous melanoma from 1982 to 2011 were included;
the final sample size was 185,219. The outcome was survival; both
cause-specific and all-cause mortality were examined. The main
exposure was race/ethnicity. Kaplan–Meier survival analysis was used
to estimate overall survival. Cox proportional hazards regression was
used to estimate unadjusted and adjusted hazard ratios (HRs). A P-value
less than 0.05 was considered statistically significant.
More than 50% of patients in all races/ethnicities were diagnosed at
the in situ or localized stage. Non-Hispanic White patients were more
frequently diagnosed at the in situ stage. Overall, more men were
diagnosed than women. The majority of cases among all races were
men. Non-Hispanic Black females represented the smallest percentage of
melanoma cases among all races. The smallest number of diagnoses
across all races/ethnicities was made from 1982 to 1991. Median follow-
up was 81 months and no collinearity was observed in the adjusted models.
When examining cause-specific mortality and controlling for site and
stage at diagnosis, gender, age and decade of diagnosis, the HR for non-
Hispanic Black patients was lower than that for non-Hispanic White
patients (HR 0.7; 95% confidence interval (CI): 0.6–0.8). However, when
examining all-cause mortality, this difference disappeared (HR 1.1; 95%
CI: 1.0–1.2). Stage at diagnosis impacted HR; patients diagnosed with
distant metastases had significantly worse survival.
When taking cause-specific mortality into consideration and after
controlling for stage and site at diagnosis, gender, and age and decade of
diagnosis, non-Hispanic Black patients had a lower HR compared to non-
Hispanic White patients. However, this difference disappeared when
examining all-cause mortality. Further research is needed to explore this
finding and to determine what factors may be associated with late-stage
melanoma diagnosis.
(Medicine 95(17):e3315)
Abbreviations: CI = confidence interval, HR = hazard ratio,
SEER = National Cancer Institute’s Surveillance, Epidemiology,
and End Results Program, U.S. = United States.
INTRODUCTION
M elanoma is an aggressive skin cancer originating frommelanocytes, the cells which are normally responsible for
the production of pigments in the basal layer of epidermis. Of
the various skin cancers that are known, melanoma is the most
aggressive type. While it accounts for only around 5% of all skin
cancers, it is responsible for 75% of deaths among skin cancer
patients.1
Melanoma is preventable and treatable. It is often caused
by ultraviolet radiation from sunshine or tanning beds. Certain
factors have been shown to increase the lifetime risk to develop
melanoma such as light eyes, red hair, fair skin, abundance of
freckles, and multiple or dysplastic moles.2 There were around
55,000 deaths from malignant melanoma worldwide in 2012
(0.7% of total cancer deaths).3 Globally, Australia and New
Zealand have the highest melanoma incidence.4 In the United
States (U.S.), melanoma incidence is increasing.5 According to
Sandru et al,6 the likelihood of getting melanoma has increased
from 1:1500 in 1935 to 1:50 in 2011. Melanoma-related
mortality rates are increasing as well.5
The highest incidence according to SEER was in Cauca-
sians (29.7 males and 19.1 females per 100,000), followed by
Hispanics (4.4 males and 4.7 females per 100,000), then by
Asians and Blacks (1.1 males and 1.0 females per 100,000).7
Previous studies have found that race/ethnicity may play a role
in survival among melanoma patients.8 Stage at diagnosis is an
important factor when determining prognosis; site may also
play a role in survival.5
To our knowledge, there are no studies available which
examined differences in survival among melanoma patients by
race/ethnicity over a period of 30 years in the U.S. The objective
of this study was to examine the differences in survival by race/
ethnicity, taking stage and site at diagnosis into account, among
U.S. melanoma patients over 3 decades.
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METHODS
Study Design
This study was a secondary analysis of publicly available
data from the National Cancer Institute’s Surveillance, Epide-
miology, and End Results (SEER) Program, which collects
incidence and survival data for patients with malignant tumors
through selected population-based cancer registries across the
United States (U.S.), representative of approximately 30% of
the American population.9 Adults (18 years or older) diagnosed
with primary cutaneous melanoma from 1982 to 2011 were
included in the study. After excluding duplicate patients,
patients below 18 years, patients diagnosed before 1982, and
patients missing survival information, the final sample size was
185,219.
The outcome of interest was overall survival, for both
cause-specific and all-cause mortality. The main exposure of
interest was race/ethnicity. Possible confounders included stage
at diagnosis, site at diagnosis, gender, age at diagnosis, and
decade of diagnosis. Race/ethnicity was grouped as non-His-
panic White, non-Hispanic Black, Hispanic, or Other (Asian or
Pacific Islander, American Indian/Alaska Native, and other
unspecified). Stage at diagnosis was categorized as in situ,
localized, regional, and distant. Site was classified into head
and neck, trunk, upper limb, and lower limb. Eyelid and ears
were considered part of the head and neck category.10 Age at
diagnosis was categorized as less than 30 years, 30 to 39, 40 to
49, 50 to 59, 60 to 69, or 70 years or older. Decade of diagnosis
was categorized as 1982 to 1991, 1992 to 2001, and 2002
to 2011.
Statistical Analysis
The Chi-square test was used to study bivariate associations
between categorical variables. Kaplan–Meier survival analysis
was used to estimate the unadjusted survival curves by race for
both cause-specific and all-cause mortality. Cox proportional
hazards regression was used to estimate unadjusted and adjusted
hazard ratios (HRs). Collinearity was assessed using Pearson
correlation. Three different adjusted models were estimated for
both cause-specific and all-cause mortality: 1 which included site
at diagnosis, gender, age and decade of diagnosis; 1 which
substituted stage at diagnosis for site; and 1 which included
both site and stage at diagnosis. A P-value less than 0.05 was
considered statistically significant. Statistical analysis was com-
pleted using SPSS version 22 (IBM, Armonk, NY). This sec-
ondary data analysis utilized data that is publicly available
through the SEER website. Ethical approval was waived since
the analysis was considered nonhuman subjects research by the
Florida International University Health Sciences IRB.
RESULTS
Table 1 describes the demographic and clinical character-
istics of adult patients with primary cutaneous melanoma pre-
sent in the SEER registry from 1982 to 2011. More than 50% of
patients in all races/ethnicities groups were diagnosed at the in
TABLE 1. Demographic Characteristics of U.S. Adult Patients With Primary Cutaneous Melanoma, 1982–2011 (N¼185,219)
Race/Ethnicity
Characteristics NHW 169,844 (%) NHB 3070 (%) Hispanic 4616 (%) Othery 2303 (%) P
Stage at diagnosis <0.001
In situ 33.4 12.1 27.9 23.7
Localized 56.9 53.1 56.2 52.5
Regional 7.3 27.6 12.1 18.5
Distant 2.3 7.1 3.8 5.3
Site at diagnosis <0.001
Head and neck 26.5 14.5 24.7 25.7
Trunk 31.0 25.2 25.8 28.1
Upper limb 23.9 17.1 20.6 17.7
Lower limb 18.6 43.2 28.9 28.5
Gender <0.001
Male 56.8 71.9 55.1 56.6
Female 43.2 28.1 44.9 43.4
Age at diagnosis <0.001
<30 years old 5.7 14.7 10.2 8.6
30–39 years old 13.1 33.3 25.8 17.4
40–49 years old 17.9 22.8 20.6 18.5
50–59 years old 19.7 10.4 14.1 17.2
60–69 years old 18.9 8.2 12.7 13.2
70 years old 24.7 10.7 16.7 25.1
Decade of diagnosis <0.001
1982–1991 20.9 27.4 24.9 19.8
1992–2001 32.8 39.9 33.5 37.1
2002–2011 46.3 32.7 41.6 34.1
NHB¼ non-Hispanic Black, NHW¼ non-Hispanic White.
yOther race/ethnicity includes Asian or Pacific Islander, American Indian/Alaska Native, and other unspecified.
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situ or localized stage. Non-Hispanic White patients were more
frequently diagnosed at the in situ stage. The highest percentage
of patients diagnosed at distant stage were non-Hispanic Blacks
at 7.1%, followed by patients of other races at 5.3%. Melanoma
was commonly located in the lower limb for non-Hispanic
Black, Hispanic, and patients of other races (43.2%, 28.9%,
and 28.5%, respectively), while melanoma in non-Hispanic
White patients was most frequently located in the trunk
(31.0%).
The majority of cases among all races were men. Non-
Hispanic Black females represented the smallest percentage of
melanoma cases among all races/ethnicities. Patients less than
30 years old at diagnosis contributed the smallest proportion in
each race, except for non-Hispanic Black patients, for whom the
smallest proportion was diagnosed at 60 to 69 years of age. Non-
Hispanic White and patients of other races were more frequently
diagnosed at age of 70 years or above, while most Hispanic and
non-Hispanic Black patients were diagnosed at 30 to 39 years.
The smallest number of diagnoses across all races/ethnicities
was made from 1982 to 1991.
The unadjusted overall survival curves by race are shown
for cause-specific and all-cause mortality in Figures 1 and 2,
respectively. Median follow-up time was 81 months. Non-
Hispanic Blacks had the worst unadjusted survival compared
to other races.
Table 2 shows the unadjusted and adjusted HRs of cause-
specific mortality for primary cutaneous melanoma among
U.S. adult patients, 1982 to 2011. In the unadjusted model,
non-Hispanic Black patients had the highest HR of 4.3 (95%
confidence interval (CI): 4.0–4.5) in comparison with the
reference group of non-Hispanic White patients. No collinear-
ity was observed in the adjusted models. In Adjusted Model 1a,
which adjusted for site at diagnosis, gender, and age and decade
of diagnosis, the HR for non-Hispanic Black patients remained
high compared to non-Hispanic Whites (HR 3.0; 95% CI: 2.7–
3.3). In Adjusted Model 2a, which substituted stage at diag-
nosis for site, the HR for non-Hispanic Black patients was 30%
better compared to non-Hispanic White patients (HR 0.7;
95% CI: 0.6–0.8). In Adjusted Model 3a, which included both
site and stage at diagnosis, the HR for non-Hispanic Black
patients remained virtually unchanged (Figure 3). Stage at
diagnosis had an important impact on HR. Those diagnosed
with localized melanoma had an HR of 5.8 (95% CI: 5.3–6.3),
those diagnosed with regional melanoma had an HR of
31.5 (95% CI: 28.9–34.2), and those diagnosed with distant
metastases had an HR of 169.6 (95% CI: 154.2–186.6), com-
pared to the reference group of in situ diagnosis. Women had a
lower hazard of death compared to men (HR 0.6; 95% CI: 0.6–
0.7). Patients diagnosed in 1982 to 1991 had a higher HR
compared to those diagnosed in 2002 to 2011 (HR 1.7; 95% CI:
1.6–1.8).
Table 3 shows the unadjusted and adjusted HRs of all-
cause mortality for primary cutaneous melanoma among U.S.
adult patients, 1982 to 2011. In the unadjusted model, non-
Hispanic Black patients had the highest HR of 2.6 (95% CI:
2.5–2.7) in comparison with the reference group of non-His-
panic White patients. No collinearity was observed in the
adjusted models. In Adjusted Model 1b, which adjusted for
site at diagnosis, gender, and age and decade of diagnosis, the
HR for non-Hispanic Black patients remained high compared to
non-Hispanic Whites (HR 2.5; 95% CI: 2.4–2.7). However, in
Adjusted Model 2b, which substituted stage at diagnosis for site,
there was no significant difference between non-Hispanic
Blacks and the reference group of non-Hispanic Whites (HR
1.0; 95% CI: 0.9–1.1). Similarly, in Adjusted Model 3b, which
included both site and stage at diagnosis, no significant differ-
ence was observed between non-Hispanic Blacks and non-
Hispanic Whites (Figure 4). Stage at diagnosis had an important
impact on HR. Those diagnosed with localized melanoma had
an HR of 1.5 (95% CI: 1.5–1.5), those diagnosed with regional
melanoma had an HR of 3.9 (95% CI: 3.8–4.1), and those
diagnosed with distant metastases had an HR of 15.8 (95% CI:
14.9–16.7), compared to the reference group of in situ diag-
nosis. Individuals diagnosed with melanoma in the trunk, upper
limb, and lower limb had a slightly better HR compared to
individuals diagnosed with melanoma in the head and neck.
Women had a lower hazard of death compared to men (HR 0.7;
95% CI: 0.7–0.7). Patients diagnosed in 1982 to 1991 had a
higher HR compared to those diagnosed in 2002 to 2011 (HR
1.5; 95% CI: 1.4–1.5).
FIGURE 1. Unadjusted survival curve by race/ethnicity, cause-
specific mortality, among U.S. adult patients with primary
cutaneous melanoma, 1982–2011 (N¼185,219).
FIGURE 2. Unadjusted survival curve by race/ethnicity, all-cause
mortality, among U.S. adult patients with primary cutaneous
melanoma, 1982–2011 (N¼185,219).
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DISCUSSION
The full adjusted model for cause-specific mortality
showed that non-Hispanic Black patients had a 30% better
hazard of death compared to non-Hispanic White patients
(Adjusted Model 3a). This finding may be related to a biological
effect due to the high melanin production in darker skins.11,12
However, in the full adjusted model for all-cause mortality, the
difference between non-Hispanic Black and non-Hispanic
White patients disappeared (Adjusted Model 3b). One expla-
nation may be due to social inequities; further research is
needed to fully explore this finding.4,8,13
The impact of stage at diagnosis remained high in the full
adjusted models for both cause-specific and all-cause mortality
(Adjusted Models 3a and 3b). The finding that stage at diagnosis
is an important prognostic factor aligns with other similar
studies in the literature.5 Future research should explore more
fully what demographic factors are associated with late-stage
diagnosis among U.S. patients with melanoma, taking socio-
economic status, education, and insurance status into account.4
Hispanic and patients of other races were very similar to
the non-Hispanic White reference group. Additionally, the
TABLE 2. Unadjusted and Adjusted Hazard Ratios, Cause-Specific Mortality, Among U.S. Adult Patients With Primary Cutaneous
Melanoma, 1982–2011 (N¼185,219)
Characteristics
Unadjusted Adjusted 1a Adjusted 2a Adjusted 3a
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Race/ethnicity
Non-Hispanic White Ref Ref Ref Ref
Non-Hispanic Black 4.3 (4.0–4.5) <0.001 3.0 (2.7–3.3) <0.001 0.7 (.6-.8) <0.001 0.7 (0.6–0.8) <0.001
Hispanic 2.2 (2.0–2.3) <0.001 1.8 (1.6–2.0) <0.001 1.1 (.9–1.2) 0.38 1.1 (1.0–1.2) 0.26
Othery 1.8 (1.6–1.9) <0.001 1.6 (1.4–1.8) <0.001 0.9 (.8–1.0) 0.03 0.9 (0.8–1.0) 0.14
Stage at diagnosis
In situ Ref — Ref Ref
Localized 5.3 (5.0–5.8) <0.001 — 5.7 (5.3–6.2) <0.001 5.8 (5.3–6.3) <0.001
Regional 31.3 (28.8–34.0) <0.001 — 31.7 (29.2–34.4) <0.001 31.5 (28.9–34.2) <0.001
Distant 202.4 (186.2–22.1) <0.001 — 189.8 (174.4–206.5) <0.001 169.6 (154.2–186.6) <0.001
Site at diagnosis
Head and neck Ref Ref — Ref
Trunk 1.0 (0.9, 1.0) 0.02 1.1 (1.0–1.1) <0.001 — 1.0 (1.0–1.1) 0.15
Upper limb 0.8 (0.7, 0.8) <0.001 0.95 (0.91–1.00)

0.04 — 0.8 (0.7–0.8) <0.001
Lower limb 1.1 (1.0, 1.1) 0.001 1.6 (1.5–1.6) <0.001 — 1.0 (1.0–1.1) 0.75
Gender
Male Ref Ref Ref Ref
Female 0.4 (0.3–0.4) <0.001 0.4 (0.4–0.5) <0.001 0.7 (0.6–0.7) <0.001 0.6 (0.6–0.7) <0.001
Age at diagnosis
<30 years old Ref Ref Ref Ref
30–39 years old 1.6 (1.5–1.7) <0.001 1.4 (1.3–1.5) <0.001 1.3 (1.1–1.4) <0.001 1.3 (1.2–1.4) <0.001
40–49 years old 1.1 (1.0–1.1) 0.48 1.2 (1.1–1.3) <0.001 1.6 (1.4–4.7) <0.001 1.6 (1.4–1.8) <0.001
50–59 years old 0.7 (0.7–0.8) <0.001 1.1 (1.0–1.2)

0.006 1.9 (1.8–2.1) <0.001 2.0 (1.8–2.2) <0.001
60–69 years old 0.8 (0.8–0.9) <0.001 1.3 (1.2–1.4) <0.001 2.4 (2.2–2.6) <0.001 2.5 (2.3–2.8) <0.001
70 years old 1.2 (1.1–1.2) <0.001 2.2 (2.0–2.4) <0.001 3.5 (3.2–3.9) <0.001 4.0 (3.6–4.4) <0.001
Decade of diagnosis
1982–1991 3.5 (3.3–3.6) <0.001 2.6 (2.4–2.7) <0.001 1.6 (1.5–1.7) <0.001 1.7 (1.6–1.8) <0.001
1992–2001 2.0 (1.9–2.1) <0.001 1.6 (1.5–1.7) <0.001 1.3 (1.2–1.3) <0.001 1.3 (1.2–1.4) <0.001
2002–2011 Ref Ref Ref Ref
CI¼ confidence interval, HR¼ hazard ratio, NHB¼ non-Hispanic Black, NHW¼ non-Hispanic White.
95% confidence interval includes 1 due to rounding.
yOther race/ethnicity includes Asian or Pacific Islander, American Indian/Alaska Native, and other unspecified.
FIGURE 3. Adjusted survival curve by race/ethnicity, cause-
specific mortality, among U.S. adult patients with primary
cutaneous melanoma, 1982–2011 (N¼185,219).
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aging process increased HR, which was expected. Observing the
number of cases diagnosed from 1982 to 1991, the smallest
number of diagnoses across all races/ethnicities were made in
that period. This could be due to low screening rates or lower
knowledge compared to the present day. While this study did
not examine incidence, results showed men were diagnosed
more frequently than women overall. In contrast, Wu et al13
found that melanoma incidence was higher for Hispanic and
non-Hispanic Black women younger than 49 compared to men;
after the age of 49, incidence was higher for men. The improved
HRs for women compared to men were similar to another study
which found that, among non-Hispanic White adolescents and
young adults with melanoma, men have worse survival after
controlling for thickness and other prognostic factors.14
The main strength of this study was the use of high-quality
SEER data and the large sample size of melanoma cases. One
weakness was that about 12% of cases had to be excluded
because they were missing information. Furthermore, the fol-
low-up period was not the same for all 3 decades. Finally, this
study did not account for all factors that might have an impact
on survival such as treatment regimens, prognostic factors
(such as Breslow thickness, Clark level, mitoses, ulceration,
TABLE 3. Unadjusted and Adjusted Hazard Ratios, All-Cause Mortality, Among U.S. Adult Patients With Primary Cutaneous
Melanoma, 1982–2011 (N¼185,219)
Characteristics
Unadjusted Adjusted 1b Adjusted 2b Adjusted 3b
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Race/ethnicity
Non-Hispanic White Ref Ref Ref Ref
Non-Hispanic Black 2.6 (2.5–2.7) <0.001 0.7 (1.7–0.8) <0.001 1.0 (0.9–1.1) 0.54 1.1 (1.0–1.2) 0.17
Hispanic 1.5 (1.4–1.6) <0.001 0.5 (0.5–0.5) <0.001 1.1 (1.0–1.1) 0.08 1.1 (1.0–1.2)

0.05
Othery 1.4 (1.3–1.5) <0.001 Ref <0.001 0.9 (0.9–1.0) 0.18 1.0 (0.9–1.1) 0.79
Stage at diagnosis
In situ Ref — Ref Ref
Localized 1.1 (1.1–1.1) <0.001 — 1.4 (1.4–1.5) <0.001 1.5 (1.5–1.5) <0.001
Regional 3.4 (3.3–3.5) <0.001 — 3.8 (3.7–3.9) <0.001 3.9 (3.8–4.1) <0.001
Distant 18.4 (17.7–19.1) <0.001 — 18.0 (17.3–18.7) <0.001 15.8 (14.9–16.7) <0.001
Site at diagnosis
Head and neck Ref Ref — Ref
Trunk 0.5 (0.5–0.6) <0.001 0.9 (0.9–0.9) <0.001 — 0.9 (0.8–0.9) <0.001
Upper limb 0.6 (0.6–0.6) <0.001 0.9 (0.9–0.9) <0.001 — 0.8 (0.8–0.8) <0.001
Lower limb 0.5 (0.5–0.5) <0.001 1.0 (1.0–1.1) 0.006 — 0.8 (0.8–0.8) <0.001
Gender
Male Ref Ref Ref Ref
Female 0.5 (0.5–0.5) <0.001 0.6 (0.6–0.6) <0.001 0.7 (0.7–0.7) <0.001 0.7 (0.7–0.7) <0.001
Age at diagnosis
<30 years old Ref Ref Ref Ref
30–39 years old 1.6 (1.6–1.7) <0.001 1.5 (1.4–1.6) <0.001 1.3 (1.2–1.5) <0.001 1.4 (1.2–1.5) <0.001
40–49 years old 1.2 (1.2–1.3) <0.001 1.6 (1.4–1.7) <0.001 2.0 (1.9–2.2) <0.001 2.1 (1.9–2.3) <0.001
50–59 years old 1.3 (1.2–1.4) <0.001 2.1 (2.0–2.3) 0.006 3.4 (3.2–3.7) <0.001 3.5 (3.2–3.9) <0.001
60–69 years old 2.3 (2.2–2.4) <0.001 4.1 (3.8–4.4) <0.001 6.8 (6.3–7.4) <0.001 7.2 (6.6–7.9) <0.001
70 years old 5.8 (5.5–6.1) <0.001 11.6 (10.8–12.4) <0.001 18.8 (17.3–20.3) <0.001 20.5 (18.8–22.3) <0.001
Decade of diagnosis
1982–1991 0.7 (1.7–0.8) <0.001 1.9 (1.8–1.9) <0.001 1.4 (1.4–1.5) <0.001 1.5 (1.4–1.5) <0.001
1992–2001 0.5 (0.5–0.5) <0.001 1.4 (1.4–1.4) <0.001 1.2 (1.2–1.2) <0.001 1.2 (1.2–1.2) <0.001
2002–2011 Ref Ref Ref Ref
CI¼ confidence interval, HR¼ hazard ratio, NHW¼ non-Hispanic White; NHB¼ non-Hispanic Black.
95% confidence interval includes 1 due to rounding.
yOther race/ethnicity includes Asian or Pacific Islander, American Indian/Alaska Native, and other unspecified.
FIGURE 4. Adjusted survival curve by race/ethnicity, all-cause
mortality, among U.S. adult patients with primary cutaneous
melanoma, 1982–2011 (N¼185,219).
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and serum lactate dehydrogenase), and demographic factors
(such as socioeconomic status, education, and insurance status).
When taking cause-specific mortality into consideration and
after controlling for stage and site at diagnosis, gender, and age and
decade of diagnosis, non-Hispanic Black patients had a lower HR
compared to non-Hispanic White patients. However, this differ-
ence disappeared when examining all-cause mortality. Further
research is needed to explore this finding and to determine what
factors may be associated with late-stage melanoma diagnosis.
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